A peptide comprising the rhinovirus immunogen peptide of the rhinovirus structural protein 1 (VP1) of rhinovirus C and related vaccines and therapeutic compositions is disclosed.

Novel compositions useful as human rhinovirus immunogens are provided. The compositions enable a host response to sites normally not recognized by a host.

Novel compositions useful as human rhinovirus immunogens are provided. The compositions enable a host response to sites normally not recognized by a host.

A peptide comprising the rhinovirus immunogen peptide of the rhinovirus structural protein 1 (VP1) of rhinovirus C and related vaccines and therapeutic compositions is disclosed.

The present invention belongs to the field of immunobiology, and relates to an epitope polypeptide, such as a general affinity epitope polypeptide of human rhinovirus, and the use thereof. The present invention further relates to an antibody capable of binding to the epitope polypeptide and the use thereof. The present invention further relates to the use of the affinity epitope polypeptide or the antibody in the preparation of drugs or in methods for treating and/or preventing and/or diagnosing human rhinovirus and/or identifying a titer of human rhinovirus and/or identifying a titer of a neutralizing antibody of human rhinovirus. The affinity epitope polypeptide and antibody can be used in drugs or methods for treating and/or preventing and/or diagnosing human rhinovirus and/or identifying a titer of human rhinovirus and/or identifying a titer of a neutralizing antibody of human rhinovirus.

Novel compositions useful as human rhino virus immunogens are provided. The compositions enable a host response to sites normally not recognized by a host.

Novel compositions useful as human rhinovirus immunogens are provided. The compositions enable a host response to sites normally not recognized by a host.